GeneDx Holdings Corp. (WGS) earnings date
Feb 23, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Mon, Aug 3, 2026 | after close | 34 | 8-K |
| Q1 FY2026 | Mon, May 4, 2026 | after close | 34 | 8-K |
| Q4 FY2025 | Mon, Feb 23, 2026 | before open | 54 | 8-K |
| Q3 FY2025 | Tue, Oct 28, 2025 | before open | 28 | 8-K |
| Q2 FY2025 | Tue, Jul 29, 2025 | before open | 29 | 8-K |
| Q1 FY2025 | Wed, Apr 30, 2025 | before open | 30 | 8-K |
| Q4 FY2024 | Tue, Feb 18, 2025 | before open | 49 | 8-K |
What they guided beta
| Q3 FY2026 | "Reiterating full year 2026 revenue guidance of $475 to $490 million" exhibit Read from the sentence: revenue $475 million to $490 million, FY2026 |
| Q3 FY2026 | "GeneDx 2026 Guidance GeneDx has updated its 2026 guidance and has provided guidance for the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "Management expects GeneDx to deliver: Metric Full Year 2026 Previous Guidance Full Year 2026 Updated Guidance Fourth Quarter 2026 Guidance Revenue $475 to $490 million $475 to $490 million $135 million Exome and genome volume At least 30% growth At least 28% growth 34,500 tests Exome and genome revenue At least 20% growth At least 17% growth $121 million Adjusted gross margin Approximately 70% Approximately 71% At least 71% Adjusted net income Positive Approximately $12 million Approximately $12 million Third Quarter 2026 and Recent Business Highlights Strategic Expansion and Market Leadership" exhibit |
| Q2 FY2026 | "Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30%" exhibit |
| Q2 FY2026 | "GeneDx 2026 Guidance GeneDx has reaffirmed its full year 2026 guidance and has provided guidance for the third quarter of 2026." exhibit |
| Q2 FY2026 | "Management expects GeneDx to deliver: Metric Full Year 2026 Guidance Third Quarter 2026 Guidance Revenue $475 to $490 million $122 to $124 million Exome and genome volume At least 30% growth 33,200 tests Exome and genome revenue At least 20% growth $110 to $112 million Adjusted gross margin Approximately 70% Approximately 70% Adjusted net income Positive Approximately $2 million Second Quarter 2026 and Recent Business Highlights Strategic Expansion and Market Leadership" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/WGS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/WGS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/WGS/"><img src="https://veritasdata.dev/embed/WGS.svg" alt="WGS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/WGS/)
Script
<script async src="https://veritasdata.dev/embed/WGS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/WGS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.